Biogen Pharmachem Industries Limited

BSE:531752 Stock Report

Market Cap: ₹802.7m

Biogen Pharmachem Industries Past Earnings Performance

Past criteria checks 0/6

Biogen Pharmachem Industries has been growing earnings at an average annual rate of 45.3%, while the Capital Markets industry saw earnings growing at 29.6% annually. Revenues have been declining at an average rate of 1.8% per year.

Key information

45.3%

Earnings growth rate

60.5%

EPS growth rate

Capital Markets Industry Growth20.7%
Revenue growth rate-1.8%
Return on equity-0.6%
Net Margin24.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Biogen Pharmachem Industries makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BSE:531752 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24-15-400
30 Jun 24151400
31 Mar 2481910
31 Dec 23101020
30 Sep 23121220
30 Jun 23252520
31 Mar 233520
31 Dec 2210400
30 Sep 227100
30 Jun 22-3-1810
31 Mar 2225010
31 Dec 2161800
30 Sep 2139-1400
30 Jun 2129-1400
31 Mar 2116-1600
31 Dec 200-2300
30 Sep 200-100
30 Jun 200-100
31 Mar 200-100
31 Dec 195000
30 Sep 199000
30 Jun 199000
31 Mar 199000
31 Dec 185-6500
30 Sep 180-6600
30 Jun 180-6700
31 Mar 180-6600
31 Dec 170-110
30 Sep 170-110
30 Jun 170-110
31 Mar 170-100
31 Dec 160000
30 Sep 160000
30 Jun 160000
31 Mar 160000
31 Dec 150-100
30 Sep 150-100
30 Jun 150-100
31 Mar 150-100
31 Dec 140-100
30 Sep 140-100
30 Jun 140-100
31 Mar 140-100

Quality Earnings: 531752 is currently unprofitable.

Growing Profit Margin: 531752 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 531752 is unprofitable, but has reduced losses over the past 5 years at a rate of 45.3% per year.

Accelerating Growth: Unable to compare 531752's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 531752 is unprofitable, making it difficult to compare its past year earnings growth to the Capital Markets industry (50.1%).


Return on Equity

High ROE: 531752 has a negative Return on Equity (-0.64%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies